

Edgar Filing: CELGENE CORP /DE/ - Form 8-K

CELGENE CORP /DE/  
Form 8-K  
March 23, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 23, 2007

CELGENE CORPORATION  
(Exact name of registrant as specified in its charter)

Delaware	0-16132	22-2711928
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

86 Morris Avenue, Summit, New Jersey	07901
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (908) 673-9000

-----  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CELGENE CORP /DE/ - Form 8-K

ITEM 8.01 OTHER EVENTS

On March 23, 2007, Celgene Corporation announced that REVLIMID(R) (lenalidomide) has received a positive opinion from the European Medicines Agency (EMA) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for REVLIMID(R). The CHMP's positive opinion will be forwarded to the European Commission that generally follows the recommendation of the CHMP and issues final marketing approval within two to three months.

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcing such information.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibit 99.1 - Press Release dated March 23, 2007

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELGENE CORPORATION

Date: March 23, 2007

By: /s/ David W. Gryska

-----  
Name: David W. Gryska  
Title: Sr. Vice President and  
Chief Financial Officer